SOD1 and amyotrophic lateral sclerosis: However, although Qalsody (Tofersen) performed well in terms of safety and tolerability and showed some degree of neuroprotection, it failed to meet the primary endpoints of reducing SOD1 protein levels and improving ALS functional scores in a phase III clinical trial (40).